Summary
Gilead Sciences, Inc. (GILD) has filed an 8-K report on June 23, 2005, to announce the termination of its Development and License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. concerning the co-developed influenza treatment and prevention drug, Tamiflu® (oseltamivir phosphate). This termination is based on an alleged material breach of the 1996 Agreement by Roche. If the termination becomes effective, Gilead would regain all licenses granted to Roche under the agreement, potentially allowing Gilead to re-assume control over the manufacturing and sales of Tamiflu. This event could significantly impact Gilead's future revenue streams and strategic direction concerning its antiviral portfolio. Investors should monitor the developments and potential legal proceedings arising from this termination notice.
Key Highlights
- 1Gilead Sciences has issued a notice of termination to Roche for a material breach of the 1996 Development and License Agreement related to Tamiflu.
- 2The termination pertains to the co-development and commercialization of the antiviral drug Tamiflu® (oseltamivir phosphate).
- 3Roche currently holds exclusive rights to manufacture and sell Tamiflu worldwide under the agreement.
- 4If the termination becomes effective, Gilead would regain all licenses granted to Roche, potentially allowing Gilead to reclaim control of Tamiflu.
- 5The agreement stipulated that Roche pays Gilead a percentage of net revenues from Tamiflu sales, subject to certain cost reductions.
- 6This action signifies a potential major shift in Gilead's relationship with Roche and its control over a key product.